Dr. Omar Nadeem, MD

Dr. Nadeem practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.

Dr. Nadeem's NPI, 1215170691, was assigned on April 14, 2009. Dr. Nadeem graduated from Ross University School of Medicine in 2009. Dr. Nadeem's Massachusetts license number on file is 261852.

Dr. Nadeem's primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.

Dr. Nadeem's primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dr. Nadeem is also affiliated with Brigham and Women's Hospital. The medical group on file is Binney Medical Group. Dmand AI also links Dr. Nadeem to 2 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nadeem practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Nadeem's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dmand AI has Dr. Nadeem's licenses on file in 6 states: Massachusetts, Florida, Rhode Island, Vermont, Connecticut and Maine.

Dmand AI lists chronic anemia, chronic leukemia, immune deficiency disease, multiple myeloma and prostate cancer among the conditions Dr. Nadeem treats.

CMS data shows 578 Medicare services from Dr. Nadeem across 6 procedure codes in 2024, for 333 Medicare patients. Medicare paid $55,363 for them.

CMS counts 333 Medicare patients who saw Dr. Nadeem in 2024. The largest group is 65 to 74, with 160 patients. 72% of them have high cholesterol, and 70% have high blood pressure. 14% are also on Medicaid. Their average risk score is 2.49, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nadeem's median patient age at 71, with 48% women.

In 2024, Dr. Nadeem wrote 118 Medicare Part D claims for 59 patients. 54% of them were for generic drugs. CMS names the drug for 44 of them, across 2 drugs with 11 or more claims each, at $544,129 in total drug cost. In 2023, CMS named 257 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Nadeem for performance year 2024, reported as part of a group. Dr. Nadeem accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Nadeem as offering telehealth.

Dmand AI links 62 papers to Dr. Nadeem, published from 2012 to 2025. 2024 was the busiest year, with 15. The most frequent topics are Multiple Myeloma, Antineoplastic Agents and Antineoplastic Combined Chemotherapy Protocols. Dr. Nadeem has published most often in Blood Adv. Dr. Nadeem's most frequent co-authors are Jacob P. Laubach, MD, Kenneth C. Anderson, MD and Adam Samuel Abdur-Rahim Sperling, MD, PhD.

Dmand AI links Dr. Nadeem to 8 clinical trials, 4 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Monoclonal Gammopathy of Undetermined Significance. Takeda sponsors the most, 3.

CMS Open Payments shows 174 general payments to Dr. Nadeem from 18 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 73% of the total. Celgene Corporation paid the most, $58,644.

Dr. Nadeem graduated from Ross University School of Medicine in 2009.

Dr. Nadeem is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.